1-01.jpg

At the Heart of Innovation 

CardiaTec is applying artificial intelligence on large-scale multi-omic data to develop the next generation of cardiovascular disease drug targets

Cardiovascular Disease 

The Leading Global Cause of Death 

Cardiovascular disease has been the leading global cause of death since the 1970s and claims over 17 million lives each year - to put this into perspective, every minute some dies from a cardiovascular event. 

Despite its impact, research & development in the cardiovascular field has been massively underfunded compared to other indications, such as cancer and neurodegenerative disease. This has resulted in a stagnation of novel therapeutic innovation and a large unmet need for patients. As a result, there is a strong requirement for new efforts to help close the increasingly growing gap.

 

Target Discovery 

Drug Discovery 

Personalised Medicine

CardiaTec’s AI driven multi-omics analysis platform can unravel relationships that span across every layer of biology, from gene variation, methylation and expression, to their connection to proteomic and metabolomic functions. This serves to help uncover the next generation of cardiovascular disease drug targets with highly explainable biological function.

 

CardiaTec is exploring computationally enabled target-drug interactions to support the development of novel drugs into the clinic. CardiaTec's approach puts biology first for more informed drug discovery and is fully modality agnostic. 

CardiaTec is exploring patient stratification and biomarker identification to define patient endotypes most compatible to novel therapeutics to maximise patient benefitThis serves to facilitate the transition into the next paradigm of personalised medicine for cardiovascular disease, differentiating from the current one-size-fits-all standards of care.

 

Meet The Team  

 

CardiaTec spun-out of the University of Cambridge in September 2021, led by Professor Namshik Han, a world leading expert in AI for Drug Discovery and Raphael Peralta & Thelma Zablocki, alumni of the MPhil Bioscience Enterprise. Alongside them, CardiaTec’s team is composed of talented individuals underpinned by decades of computational drug discovery and industry expertise.

CardiaTec122.jpg
CardiaTec119.jpg
CardiaTec114 copy.jpg
Woochang_photo_2021.png

Prof Namshik Han

Co-Founder & CTO 

Raphael Peralta 

Co-Founder & CEO 

Thelma Zablocki

Co-Founder & COO 

Woochang Hwang 

Senior ML Engineer

Diana_Rottger_fa4ad21dee1fe003f16df1278f5cbe64_0f49406ab6.jpg

Meabh MacMahon

Senior Data Scientist

Agata Rumianek 

Senior CVD Scientist

Diana Röttger 

Board Member

Niall Santamaria 

Board Member

 

Our Investors 

logo.png

BRANDING

1632200295128.jpg

Laidlaw
Ventures 

cambridge-enterprise-logo.png

DESIGN

7620.png

CONSULTING

Crista Galli
Ventures 

pbkgfe7l3kjpzetvgp6t.webp

Apex
Ventures 

Cambridge
Enterprise 

O2h
Ventures